Online citations, reference lists, and bibliographies.
← Back to Search

Histopathology Of Parasellar Neoplasms

E. Manojlović-Gačić, Elham Rostami, N. Karavitaki, O. Casar-Borota
Published 2020 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The anatomical and histological complexity of the parasellar region as well as the presence of embryonic remnants determine the huge diversity of parasellar neoplasms. Some of them are only located in the parasellar region, whereas others can occur elsewhere, within or outside the central nervous system. Their spectrum ranges from histologically benign and low-grade malignant to high-grade malignant tumours. Although rare, metastases can pose differential diagnostic dilemmas. The severity of the clinical picture, the challenges of surgery and the risk of adverse sequelae related to surgery or radiotherapy make parasellar tumours interesting entities for the clinicians irrespective of their histological malignancy grade. Due to the different cell origins of parasellar tumours, the World Health Organization classification system does not categorise them as a distinct group. Detailed criteria for classification and malignancy grading are presented in the classification systems covering central nervous system tumours, haematological malignancies and tumours of the soft tissue and bone. In the last few years, molecular genetic features have been integrated into the diagnosis of several types of the parasellar tumours enhancing diagnostic accuracy and providing information of the value for targeting therapies. In this review, we will present histopathological and molecular genetic features, updated classification criteria and recent advances in the diagnostics and rationale for novel pharmacological therapies of selected types of parasellar neoplasms.
This paper references
10.1007/s101430100148
Intracranial dysembryogenetic tumors: pathogenesis and their order of malignancy
K. Sano (2001)
10.1055/B-0034-81699
22 Microsurgical and Endoscopic Anatomy of the Parasellar Region
A. Stamm (2011)
Über Hypophysengangsgeschwül - ste und Hirncholesteatome
J Erdheim (1904)
10.1016/j.wneu.2014.07.017
Endoscopic endonasal surgery for nonadenomatous sellar/parasellar lesions.
G. Barkhoudarian (2014)
Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations.
S. Sekine (2002)
10.1002/path.4098
Stem cell research points the way to the cell of origin for intracranial germ cell tumours
Chris Tan (2013)
10.1073/pnas.1101553108
Increased Wingless (Wnt) signaling in pituitary progenitor/stem cells gives rise to pituitary tumors in mice and humans
C. Gaston-Massuet (2011)
10.4137/CCRep.S12834
Sella Turcica Atypical Teratoid/Rhabdoid Tumor Complicated with Lung Metastasis in an Adult Female
C. Moretti (2013)
Behari S. Nonsecretory paraganglioma in cavernous sinus masquerading as meningioma
S Singh
10.1016/j.path.2017.04.008
Notochordal Tumors: An Update on Molecular Pathology with Therapeutic Implications.
Takehiko Yamaguchi (2017)
10.1002/cjp2.13
Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast‐rich mimics
N. Presneau (2015)
10.1016/j.clineuro.2014.04.026
Sellar and parasellar lesions – Clinical outcome in 61 children
C. Unsinn (2014)
10.1007/s00401-016-1557-x
Recurrent neomorphic mutations of MTOR in central nervous system and testicular germ cell tumors may be targeted for therapy
K. Ichimura (2016)
10.1007/s00701-008-1500-y
Atypical teratoid/rhabdoid tumour in sella turcica in an adult
K. Arita (2008)
10.3171/2019.8.JNS19643
Dual BRAF/MEK therapy in BRAF V600E-mutated primary brain tumors: a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity.
Aaron Bernstein (2019)
10.1007/s00401-010-0767-x
Loss of SMARCB1/INI1 expression in poorly differentiated chordomas
B. Mobley (2010)
10.18632/oncotarget.27203
Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report
M. Rao (2019)
Wholeexome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas
L Fishbein (2015)
10.5414/NPP26288
Hemangiopericytoma of the sella mimicking pituitary adenoma: case report and review of the literature.
J. Juco (2007)
10.1210/jc.2019-00012
Pituitary Metastases: A Nationwide Study on Current Characteristics With Special Reference to Breast Cancer.
Fredrika Schill (2019)
10.1007/s00401-012-0957-9
Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma
C. Andoniadou (2012)
World Health Organization Classification of Tumours of the Central Nervous System. Revised
DN Louis (2016)
10.1038/sj.bjc.6605019
Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway
N. Presneau (2009)
10.1038/81551
Mutations in SDHC cause autosomal dominant paraganglioma, type 3
S. Niemann (2000)
10.1126/SCIENCE.287.5454.848
Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma.
B. Baysal (2000)
BRAF V 600 E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB 1 - mutated adaman - tinomatous craniopharyngioma
SJ Larkin (2014)
10.1038/ng.2522
Whole exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors
J. Chmielecki (2013)
10.3171/2016.11.JNS161833
Fully endoscopic combined transsphenoidal and supraorbital keyhole approach for parasellar lesions.
Y. Nagata (2018)
10.1093/neuonc/noy035
Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma
S. Coy (2018)
Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functionalbased study
N Presneau (2011)
10.1111/J.1365-2605.2007.00793.X
Why human extragonadal germ cell tumours occur in the midline of the body: old concepts, new perspectives.
J. W. Oosterhuis (2007)
10.1038/ng.2868
Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas
P. Brastianos (2014)
10.1111/j.1440-1789.2011.01235.x
Coexistence of adamantinomatous and squamous‐papillary type craniopharyngioma: Case report and discussion of etiology and pathology
Tomu Okada (2012)
10.1007/s11060-010-0275-9
Variable methylation of the imprinted gene, SNRPN, supports a relationship between intracranial germ cell tumours and neural stem cells
Shih-Han Lee (2010)
10.1038/modpathol.2016.212
H3F3 mutation status of giant cell tumors of the bone, chondroblastomas and their mimics: a combined high resolution melting and pyrosequencing approach
T. Kervarrec (2017)
10.18632/oncotarget.23695
Exon 3 mutations of CTNNB1 drive tumorigenesis: a review
C. Gao (2018)
10.1007/s11102-015-0663-4
Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor
S. Aylwin (2015)
10.1016/j.humpath.2014.11.018
Distinct clinicopathological features of NAB2-STAT6 fusion gene variants in solitary fibrous tumor with emphasis on the acquisition of highly malignant potential.
K. Akaike (2015)
10.1007/s00401-011-0841-z
Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody
D. Capper (2011)
10.1016/c2016-1-01662-0
Encyclopedia of endocrine diseases
L. Martini (2004)
10.1038/s41467-018-02826-8
A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle
Benjamin Goode (2018)
10.1002/path.2913
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
M. F. Amary (2011)
10.1007/s00401-013-1118-5
VE1 immunohistochemistry in pituitary adenomas is not associated with BRAF V600E mutation
J. Sperveslage (2013)
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
S. Swerdlow (2017)
10.1016/j.wneu.2019.02.111
Non secretory Paraganglioma in cavernous sinus masquerading as meningioma.
S. Singh (2019)
Gene Fusion in Meningeal Hemangiopericytoma and Solitary Fibrous Tumor
10.1097/PAP.0b013e318229c004
Solitary Fibrous Tumor of the Central Nervous System: A 15-year Literature Survey of 220 Cases (August 1996–July 2011)
M. Bisceglia (2011)
10.1016/j.ajpath.2013.12.016
Solitary fibrous tumors/hemangiopericytomas with different variants of the NAB2-STAT6 gene fusion are characterized by specific histomorphology and distinct clinicopathological features.
Sarah Barthelmeß (2014)
10.1007/s00401-018-1952-6
The impact of histopathology and NAB2–STAT6 fusion subtype in classification and grading of meningeal solitary fibrous tumor/hemangiopericytoma
K. Fritchie (2018)
10.1002/cncr.11359
Malignancy in giant cell tumor of bone
F. Bertoni (2003)
10.1210/jc.2013-2000
Hypothalamic involvement predicts cognitive performance and psychosocial health in long-term survivors of childhood craniopharyngioma.
S. Fjalldal (2013)
VE 1 Antibody Immunoreactivity in Normal Anterior Pituitary and Adrenal Cortex Without Detectable BRAF V 600 E Mutations
Daniel A. Mordes (2014)
Meningeal heman - giopericytoma and solitary fibrous tumors carry the NAB 2 - STAT 6 fusion and can be diagnosed by nuclear expression of STAT 6 protein
L Schweizer (2013)
Solitary fibrous tumor of the central nervous system: a 15-year literature survey of 220 cases
M Bisceglia (1996)
10.1016/S1470-2045(09)70164-0
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis.
F. V. van Nederveen (2009)
10.1038/s41467-017-01026-0
The driver landscape of sporadic chordoma
P. Tarpey (2017)
Systematic review of clinical, radiologic, and histologic features of benign notochordal cell tumors: implications for patient management. World Neurosurg
I Usher
10.1016/J.WNEU.2019.06.009
Systematic Review of Clinical, Radiologic, and Histologic Features of Benign Notochordal Cell Tumors: Implications for Patient Management.
I. Usher (2019)
10.1086/321282
Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma.
D. Astuti (2001)
Identifica - tion of recurrent NAB 2 - STAT 6 gene fusions in solitary fibrous tumor by integrative sequenc
DR Robinson
10.1007/s00428-013-1435-z
p53 mutations may be involved in malignant transformation of giant cell tumor of bone through interaction with GPX1
Taketo Okubo (2013)
10.31487/J.COR.2019.03.05
Genetic and immune profiling for potential therapeutic targets in adult human craniopharyngioma
Cynthia Kassab (2019)
10.3171/2014.2.JNS13139
Gamma Knife radiosurgery for sellar and parasellar meningiomas: a multicenter study.
J. Sheehan (2014)
10.1055/B-002-85447
Transnasal Endoscopic Skull Base and Brain Surgery: Tips and Pearls
A. Stamm (2011)
10.1158/1078-0432.CCR-18-0139
Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma
S. Job (2018)
10.1093/jnci/djv310
Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.
P. Brastianos (2016)
10.4158/EP14481.RA
Pheochromocytoma and paraganglioma.
K. Pacak (2015)
10.1007/s00401-011-0802-6
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma
G. Schindler (2011)
10.1093/neuonc/noz139
Integrated Clinical, Histopathological, and Molecular Data Analysis of 190 Central Nervous System Germ Cell Tumors from the iGCT Consortium.
H. Takami (2019)
10.1210/jc.2011-1043
SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas.
E. Korpershoek (2011)
10.1007/s00264-016-3292-2
Recurrence of giant cell tumour of bone: role of p53, cyclin D1, β-catenin and Ki67
N. Lujić (2016)
10.1016/j.wneu.2016.05.086
Invasive Giant Cell Tumor of the Lateral Skull Base: A Systematic Review, Meta-Analysis, and Case Illustration.
Jacob L. Freeman (2016)
10.1038/ng.2509
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing
Dan R. Robinson (2013)
10.1126/science.1175689
SDH5, a Gene Required for Flavination of Succinate Dehydrogenase, Is Mutated in Paraganglioma
Huai-Xiang Hao (2009)
Rosai J. World Health Organization classification of tumours of endocrine organs
RV Lloyd (2017)
10.1007/978-981-13-1897-9_4
What’s New in Thyroid Tumor Classification, the 2017 World Health Organization Classification of Tumours of Endocrine Organs
G. Tallini (2019)
10.1097/01.pas.0000126058.18669.5d
Benign Notochordal Cell Tumors: A Comparative Histological Study of Benign Notochordal Cell Tumors, Classic Chordomas, and Notochordal Vestiges of Fetal Intervertebral Discs
Takehiko Yamaguchi (2004)
10.1210/jc.2019-01299
The Medical Therapy of Craniopharyngiomas: The Way Ahead.
K. Alexandraki (2019)
10.1002/cncr.32197
Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations
T. Juratli (2019)
10.1097/CCO.0000000000000502
Chordoma: update on disease, epidemiology, biology and medical therapies
A. Frezza (2019)
10.1007/s00401-016-1574-9
Poorly differentiated chordoma with SMARCB1/INI1 loss: a distinct molecular entity with dismal prognosis
M. Hasselblatt (2016)
10.1210/jc.2009-2170
Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas.
J. Gaal (2010)
10.1093/hmg/ddq206
SDHA is a tumor suppressor gene causing paraganglioma.
N. Burnichon (2010)
10.1016/j.wneu.2018.11.109
Primary Lymphoma of the Skull Base in the Chinese: Clinical, Radiological, Pathological, and Therapeutic Experience in a Series of 8 Patients.
X. Meng (2019)
10.1093/jnen/nlv026
NAB2-STAT6 Gene Fusion in Meningeal Hemangiopericytoma and Solitary Fibrous Tumor
K. Fritchie (2016)
10.1007/s11060-014-1562-7
Incidence of intracranial germ cell tumors by race in the United States, 1992–2010
J. Poynter (2014)
10.1158/0008-5472.CAN-08-2097
Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas.
D. Jones (2008)
Re - current papillary craniopharyngioma with BRAFV 600 E mutation treated with neoadju - vant - targeted therapy
M Rao
10.1007/s12020-018-1617-1
Molecular evaluation of a sporadic paraganglioma with concurrent IDH1 and ATRX mutations
J. Zhang (2018)
10.1016/j.wneu.2016.10.134
Unusual and Rare Locations for Craniopharyngiomas: Clinical Significance and Review of the Literature.
B. Gabel (2017)
WHO classification of tumours of soft tissue and bone
C. D. Fletcher (2013)
10.1111/his.14024
Peculiar pathological, radiological and clinical features of skull‐base de‐differentiated chordomas. Results from a referral centre case–series and literature review
S. Asioli (2019)
10.1016/J.WNEU.2019.01.094
Primary Sellar Paraganglioma: Case Report with Literature Review and Immunohistochemistry Resource.
Seán B. Lyne (2019)
10.1097/PAS.0000000000000462
Nuclear Brachyury Expression Is Consistent in Chordoma, Common in Germ Cell Tumors and Small Cell Carcinomas, and Rare in Other Carcinomas and Sarcomas: An Immunohistochemical Study of 5229 Cases
M. Miettinen (2015)
10.1002/cncr.20872
Atypical teratoid/rhabdoid tumor of the brain
A. Parwani (2005)
10.1210/JCEM.81.10.8855784
Unusual causes of sellar/parasellar masses in a large transsphenoidal surgical series.
P. Freda (1996)
Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas Assessment of BRAF V 600 E mutation status by immunohistochemistry with a mutation - specific monoclonal antibody
DA Mordes
10.1038/ng.2814
Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone
S. Behjati (2013)
10.1097/00006123-200210001-00009
The sellar region.
A. Rhoton (2002)
10.1007/s11060-005-4343-5
Malignant Giant Cell Tumor of the Skull Base Originating From Clivus and Sphenoid Bone
F. Zorlu (2005)
10.1038/ng.454
T (brachyury) gene duplication confers major susceptibility to familial chordoma
X. Yang (2009)
10.1093/jnen/nlx106
Type, Frequency, and Spatial Distribution of Immune Cell Infiltrates in CNS Germinomas: Evidence for Inflammatory and Immunosuppressive Mechanisms
Pia Zapka (2018)
10.1097/PAS.0000000000000512
Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma
Arjen H. G. Cleven (2015)
10.1002/path.1969
Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas
S. Vujovic (2006)
10.3171/2012.10.PEDS11487
The enigma of bifocal germ cell tumors in the suprasellar and pineal regions: synchronous lesions or metastasis?
J. H. Phi (2013)



Semantic Scholar Logo Some data provided by SemanticScholar